Hormone Therapy for Prostate Cancer Baltimore MD

Hormone therapy to treat advanced prostate cancer can increase the risk of heart disease, but some types of hormone therapy appear to be safer than others, new research has found. The study included 30,642 Swedish men with either locally advanced prostate cancer or prostate cancer that had spread (metastatic cancer), who had received hormone therapy as primary treatment for their cancer.

Ralph Metcalfe Howard, MD
926 W North Ave
Baltimore, MD
Specialties
Urology
Gender
Male
Education
Medical School: Howard Univ Coll Of Med, Washington Dc 20059
Graduation Year: 1959

Data Provided by:
Edward M Schaeffer, MD
(410) 955-6100
123 W Barre St Apt 105
Baltimore, MD
Specialties
Urology
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Wilmer Burton Roberts, MD
(410) 955-6070
1111 Park Ave Apt 510
Baltimore, MD
Specialties
Urology
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Stanley B Silber
(410) 332-9654
301 Saint Paul Pl
Baltimore, MD
Specialty
Urology

Data Provided by:
Walter D Devault, MD FACS
PO Box 1596
Baltimore, MD
Gender
Male
Education
Medical School: Columbia
Graduation Year: 1955

Data Provided by:
Marcel I Horowitz, MD FACS
1425 Bolton St
Baltimore, MD
Gender
Male
Education
Medical School: Chicago Med Sch
Graduation Year: 1958

Data Provided by:
Ajay R Parikh, MD
(410) 889-8899
Ste 605 Johnston Professional Bldg 3333 N Calvert
Baltimore, MD
Specialties
Urology
Gender
Male
Education
Medical School: Med Coll, Baroda Univ, Baroda, Gujarat, India
Graduation Year: 1982

Data Provided by:
Ira Edward Hantman, MD
(410) 332-9654
301 Saint Paul St Ste 802
Baltimore, MD
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Md Sch Of Med, Baltimore Md 21201
Graduation Year: 1976

Data Provided by:
Rainer Maria Ernst Engel, MD
201 E University Pkwy Ste 200
Baltimore, MD
Specialties
Urology
Gender
Male
Education
Medical School: Med Fac Rheinischen Friedrich Wilhelms Univ, Bonn, (409-02 After 1971)
Graduation Year: 1959

Data Provided by:
Michael James Naslund, MD
(410) 328-0801
419 W Redwood St Ste 320
Baltimore, MD
Specialties
Urology
Gender
Male
Education
Medical School: Johns Hopkins Univ Sch Of Med, Baltimore Md 21205
Graduation Year: 1981
Hospital
Hospital: University Of Maryland Med Sys, Baltimore, Md

Data Provided by:
Data Provided by:

Hormone Therapy for Prostate Cancer

Provided By:

TUESDAY, Sept. 22 (HealthDay News) -- Hormone therapy to treat advanced prostate cancer can increase the risk of heart disease, but some types of hormone therapy appear to be safer than others, new research has found.

The study included 30,642 Swedish men with either locally advanced prostate cancer or prostate cancer that had spread (metastatic cancer), who had received hormone therapy as primary treatment for their cancer.

The study findings were scheduled to be presented Tuesday at the European Cancer Organization meeting in Berlin.

In a news release from the European Cancer Organization, the researchers described the types of hormone therapy used: removal of the testicles to eliminate the main source of testosterone production; injections of gonadotropin-releasing hormone agonists to reduce testosterone production by the testicles; and anti-androgen pills that block testosterone from attaching to prostate cells. Most of the patients received one treatment, but 38 percent were given two types of drugs, the study authors noted.

The men were followed for an average of three years and monitored for ischemic heart disease, heart attacks, arrhythmia, and heart failure.

"We found that prostate cancer patients treated with hormone therapy had an elevated risk of developing all of the individual types of heart problems and that they were more likely than normal to die from those causes," study lead author Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London, England, said in the news release.

Specifically, hormone therapy was associated with a 24 percent increased risk of heart attack, a 19 percent increased risk of arrhythmia, a 31 percent increased risk of ischemic heart disease, and a 26 percent increased risk of heart failure, the researchers found. The increased risk of heart disease began a few months after the men began hormone therapy.

The study also found that hormone therapy was associated with a 28 percent increased risk of fatal heart attack, a 21 percent increased risk of dying from heart disease, a 26 percent increased risk of death from heart failure, and a 5 percent increased risk of fatal arrhythmia.

"In a more detailed analysis by type of hormone therapy, the lowest increase in risk for ischemic heart disease, heart attack and heart failure was seen in the group taking anti-androgen therapy, and we saw no increase in risk of death from heart disease in this group. Patients on gonadotropin-releasing hormone agonist therapy had the highest risk of these problems," Van Hemelrijck said.

The findings suggest that physicians should consider heart-related side effects when prescribing hormone therapy for prostate cancer patients and may want to refer patients to a cardiologist before the start of hormone therapy, the researchers stated.

More information

The American Urological Association Foundation has more about hormone therapy for prostate cancer.

SOURCE: European Cancer Organization, news release, Sept. 22, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com